Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) 3-Year EPS without NRI Growth Rate

: 69.80% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

Fresh Tracks Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.20.

During the past 3 years, the average EPS without NRI Growth Rate was 69.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 67.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Fresh Tracks Therapeutics was 69.80% per year. The lowest was -49.60% per year. And the median was 6.40% per year.

Competitive Comparison

For the Biotechnology subindustry, Fresh Tracks Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh Tracks Therapeutics 3-Year EPS without NRI Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's 3-Year EPS without NRI Growth Rate falls into.

Fresh Tracks Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Fresh Tracks Therapeutics (OTCPK:FRTX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Fresh Tracks Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301

Website

https://www.frtx.com

Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Executives

Monica E. Luchi	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy	director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy	officer: General Counsel and CCO	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha	officer: Chief Research & Dev. Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant	director	10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton	officer: Chief Accounting Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown	director, officer: Chief Executive Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer	officer: COO and Secretary	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru	director	C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii	officer: Chief Financial Officer
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja	officer: Chief Medical Officer	121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy	officer: Chief Business Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju	director	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301